Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA)-plasminogen activator inhibitor type 1 (PAl-1) complexes results in their clearance by Hep G2 cells. After complexes are internalized, the t-PA component is degraded. However, neither the locus of intracellular catabolism nor the fate of PAL1 has been elucidated. To characterize these aspects of t-PA.PAI-1 catabolism, the subcellular distribution of a prebound cohort of ligand molecules was delineated after internalization at 37°C. 1251-t-PA*PAI-1 and t-PA.lZ51-PAI-1 were compared in separate experiments. After ligand uptake, intracellular vesicles were separated on density gradients. Internalized 1251-t-PA.PAI-l concentrated initially in endosomes. After 20 minutes of uptake, the complex began to appear in lysosomes. Subsequently, low molecular XAMPLES OF THE involvement of plasmin-medi-E ated extracellular proteolysis in physiologic and pathologic processes include fibrinolysis, cell migration, and tumor metastasis.1,2 Conversion of the zymogen precursor plasminogen to the broad spectrum functional serine proteinase plasmin is required to initiate proteolysis by this system. Because of the pivotal role of tissue-type plasminogen activator (t-PA) as a circulating activator of plasminogen, attention has focussed on elucidating the regulatory mechanisms responsible for its rapid clearance. Several lines of evidence implicate the liver as the organ primarily involved in catabolism of t-PA.3-7 Studies concerning the particular cell type involved in t-PA clearance have shown both a role for liver parenchymal cells as well as a role for endothelial cell^.^,^ The association of t-PA with endothelial cells appears to be a mannose-mediated t-PA receptor system, whereas t-PA clearance by liver parenchymal cells is independent of oligosaccharides. The importance of the A chain of t-PA in recognition by liver receptors has been suggested by a number of studies, because the A chain of t-PA was cleared just as rapidly as intact two-chain t-PA.l0 Deletion of the growth factor domain as well as the finger domain resulted in a several-fold decrease in t-PA clearance.l1-l4 Together, these data suggest that both the finger domain and growth factor domain of t-PA are important in t-PA clearance by hepatocytes. However, because none of these mutant t-PA molecules abolish hepatic clearance completely, other domains and/or intact native conformation of t-PA appears to be required for its recognition by hepatic receptors.15-17
is independent of oligosaccharides. The importance of the A chain of t-PA in recognition by liver receptors has been suggested by a number of studies, because the A chain of t-PA was cleared just as rapidly as intact two-chain t-PA.l0 Deletion of the growth factor domain as well as the finger domain resulted in a several-fold decrease in t-PA clearance.l1-l4 Together, these data suggest that both the finger domain and growth factor domain of t-PA are important in t-PA clearance by hepatocytes. However, because none of these mutant t-PA molecules abolish hepatic clearance completely, other domains and/or intact native conformation of t-PA appears to be required for its recognition by hepatic receptors. [15] [16] [17] We have used the well-differentiated human hepatoma cell line Hep G2 as a model system to characterize catabolism of t-PA by hepatic parenchymal Plasminogen activator inhibitor type 1 (PAI-1) appears to play a critical role in modulating catabolism of t-PA by these cells. Under defined experimental conditions, a t-PA.PAI-1 complex, but not free t-PA, binds to a specific high-affinity receptor that mediates endocytosis. In this study, we examine the fate of the complex after internalization. We show that, although t-PA.PAI-1 is targeted to mature lysosomes, the individual components of the complex are degraded at markedly different rates.
ENDOCYTOSIS OF PAL1 COMPLEXES
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(St Louis, MO) or was purchased from ICN Biomedical (Costa Mesa, CA). IodoGen was obtained from Pierce (Rockford, IL) and NalZ5I was from Amersham (Arlington Heights, IL). All other chemical supplies were of analytical reagent grade and were purchased from local suppliers.
Maintenance of the Hep G2 cell line, clone a16, has been d e s~r i b e d . '~-~~~~~ Cell monolayers were grown to 80% to 90% confluence in tissue culture dishes or multiwell plates and were supplemented with fresh media 12 hours before use.
t-PA and PAI-1 were labeled with lZsI in the presence of IodoGen as described p r e v i o u~l y .~~~~~ Preformed t-PA.lEI-PAI-l complexes were generated by incubating equimolar amounts of t-PA and 'EI-PAI-l at 37°C for 30 minutes in phosphate-buffered saline (PBS). These conditions had been optimized earlier.z1 Analysis of the reaction products (see Fig 4B, left panels) indicated that approximately 50% of lZ5I-PAI-l was active as assessed by its capacity to form an SDS-stable t-PA.lEI-PAI-1 adduct. In addition, a small amount of vitronectin that had copurified with PAI-1 was present in the preparation? However, after lzI-radiolabeling, little if anyvitronectin (or fragments) could be foundz1 (see Fig 1) .
The methodology used to determine the fate of a prebound cohort of ligand molecules has been described previous1y.l8 Briefly, ligand was incubated with washed monolayers for 2 hours at 4°C in binding media (minimum essential medium Earle's/20 mmol/L 4-(2-hydroxyethy1)-1-piperazineethane-sulfonic acid/O.l mg/mL cytochrome c/pH 7.3) to allow binding to cell surface receptors. To conserve the limited supply of purified PAI-1 available, this reagent was reserved primarily for generating t-PA.Iz5I-PAI-1, whereas lZ5I-t-PA.PAI-1 was generated in situ with accessible PAI-1 present in extracellular matrix of monolayer cultures.zo~21 For 1z51-t-PA.PAI-1 binding, cells were incubated with 3 nmol/L lEI-t-PA. As shown previously, this technique leads to formation and release of 1z51-t-PA.PAI-1 complexes that subsequently bind specifically to the cell surface?O As a control, preformed lZ5I-t-PA.PA1-1 generated using purified PAI-1 was used in one experiment and gave results indistinguishable from lZ51-t-PA.PAI-1 formed in situ. For t-PA.1251-PAI-1 binding, only performed complex (1 nmol/L) was used. Next, after washing to remove unbound ligand, cells were incubated in the presence of excess unlabeled ligand (1 kmol/L) at 37°C for selected intervals to allow internalization of the prebound ligand cohort. No difference was observed when the excess unlabeled chase ligand was preformed (1 kmol/L) or was generated in situ (10 to 100 nmol/L). After each interval of ligand internalization, media were removed for detection of degraded labeled ligand fragments and cells were chilled quickly to 4°C before subcellular fractionation.
All manipulations were performed at 4°C. After each interval of ligand internalization, cells were washed twice in PBS containing 1 mmol/L EDTA. Residual ligand at the cell surface was removed proteolytically by incubating the cells for 30 minutes with 0.2 mg/mL proteinase K in the same buffer. Proteinase K activity was neutralized by the addition of 1 mmol/L PMSF and a further incubation for 10 minutes. Cells were scraped gently in this solution using a rubber policeman. Cell suspensions were centrifuged at 5% for 5 minutes and supernatants containing proteinase K-degraded ligand were aspirated. Cell pellets containing proteinase K-resistant intracellular ligand were washed twice by successive cycles of resuspension and centrifugation in homogenization buffer (0.25 mol/L sucrose, 1 mmol/L PMSF, 10 mmol/L HEPES/NaOH, pH 7.2). After a final resuspension in 600 FL of homogenization buffer, cells were disrupted by forcible passage 10 times through a 12-cm length of flexible plastic tubing (outer diameter 0.6 "/inner diameter 0.3 mm) connected snugly at each Cell culture.
Ligand preparation.
Internalization of a prebound ligand cohort.
Subcellularfractionation.
end over a 30-gauge needle attached to a 1-mL syringe.z6 Nuclei, aggregated debris, and intact cells were removed from the homogenates by centrifugation at 600g for 10 minutes. The resultant postnuclear supernatants contained 57% 2 10% of the lEI-label remaining cell-associated after proteinase K treatment. Aliquots (400 bL) of postnuclear supernatants were layered over gradient medium containing colloidal silica Percoll in 0.25 mmol/L sucrose, 10 mmol/L HEPES/NaOH, pH 7.2, before centrifugation (Beckman Ultracentrifuge L870M; Beckman Instruments Inc, Brea, CA). To resolve different populations of en do some^,^^ 7.4 mL of gradient medium containing 20% Percoll was centrifuged with the postnuclear supernatant at 33,000 rpm at 4°C for 30 minutes in a Type 70.1 Ti rotor. To resolve lysosomes and endos o m e~,~-~~ 11.3 mL of gradient medium containing 25.2% Percoll was placed over a 1.8-mL cushion of saturated sucrose before adding the postnuclear supernatant. The gradient was generated by centrifugation at 18,000 rpm at 4°C for 50 minutes with flanking 5-minute intervals for acceleration and deceleration in a VTi 65.1 rotor (Beckman Instruments). Fractions of 600 WL were collected from the bottom of each gradient. The density profile of the gradient was characterized using marker beads. Activity of the lysosomal enzyme P-hexosaminidase was measured colorimetrically using p-nitro-phenyl-N-acetyl-P-glucosaminide as s u b~t r a t e .~~,~~ The protein content of each fraction was determined using the Bradford reagent after precipitating Perco11?2 Radioactivity of each fraction was quantified by gamma-scintillation spectrometry.
Conditions for SDS-PAGE have been described p r e v i o~s l y .~~ Briefly, aliquots of all samples were solubilized directly in Laemmli buffer containing 0.2% SDS. Reducing agents were avoided and samples were not heated. The acrylamide content of each gel is stated. Labeled proteins in fixed, dried gels were detected by autoradiography as described previousContinuous uptake of ligand in the presence of lysosomotropic agents. The methodology to assess continuous specific uptake of ligand has been described.18-z0 Briefly, cells in 12-well plates were incubated at 37°C with 3 nmol/L lEI-t-PA in the absence or presence of 1 Fmol/L unlabeled t-PA to allow formation, binding, uptake, and degradation of '%t-PAPAI-l. At chosen intervals medium was aspirated, and washed cells were lysed in 1 mol/L NaOH. Radioactive material contained in the lysate was used as an index of ligand uptake. Specific uptake was defined as the difference between cell-associated radioactivity determined in the absence or presence of excess unlabeled ligand. To determine the effects of lysosomotropic agents, cells were preincubated with the selected agent for 30 minutes at 37"C. 33 Ligand was then added and the incubation was resumed in the continued presence of the lysosomotropic agent. At preselected intervals, medium was aspirated and cells were processed for determination of specific uptake of ligand. The concentrations of the lysosomotropic agents were 50 amol/L ammonium chloride, 100 pmol/L chloroquine, 200 pmol/L primaquine, 200 wg/mL leupeptin, and 100 pg/mL pepstatin A.
Media from the single cohort internalization experiments and from the continuous uptake studies were analyzed for lZ5I-labeled ligand fragments that were soluble at 4°C in 4% phosphotungstic acid/20% trichloroacetic acid as previously described.ls As determined independently by gel-filtration chromatography, the low molecular weight ( < 1 Kd) of these fragments was consistent with degradation to the level of small peptides or individual amino acids.
Ligand concentrations were determined by protein assay using the Bradford reagent with bovine serum albumin as a standard.34 The percentages of lEI-PAI-l and t-PA.lEI-PAI-l in labeled mixtures were determined by densitometry of autoradiograms." Cell number was determined by direct SDS-PAGE and autoradiography.
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Assay for ligand degradation.
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RESULTS
To delineate intracellular movement of ligand after endocytosis, the subcellular distribution of a single cohort of prebound 12sI-t-PA*PAI-l was determined after ligand uptake at 37°C for selected intervals. To establish binding, Hep G2 monolayers were incubated with IZSI-t-PA for 2 hours at 4°C. As shown previously, under these conditions exogenous IZsIt-PA combines rapidly with endogenous PAI-1 in the extracellular matrix of Hep G2 cells to form an SDS-stable ILSI-t-PA.PAI-1 complex that is reIeased.2O The ILSI-tPAePAI-1 complex formed in situ then binds specifically and with high affinity to a cell-surface receptor. At 37"C, the receptor mediates endocytosis of bound ligand. After each interval of ligand uptake, cells were processed for subcellular fractionation. Processing included rapid cooling to arrest ligand movement and metabolism, proteolytic removal of residual ligand at the cell surface, release of intracellular contents, and centrifugation to remove nuclei. The resultant postnuclear supernatants were layered over 20% Percoll and centrifuged to allow fractionation of intracellular vesicles on the basis of buoyant density. The conditions of centrifugation were chosen specifically to permit resolution of early, intermediate, and late endosomes. 27 The characteristics of the gradient are depicted in Fig  1A. The density profile of the gradient was relatively shallow between 1.04 and 1.06 g/mL (Fig lA, left panel) , the range encompassing the buoyant densities of endosomes in these cells. The lysosomal enzyme marker P-hexosaminidase was confined primarily to the densest fractions of the gradient (Fig lA, middle panel) . Its position overlapped that of late en do some^.^^ The protein distribution (Fig lA, right panel) reflects the high proportion of soluble cytosolic proteins in the postnuclear supernatant.
The distribution of vesicles containing intracellular luIlabel after different intervals of ligand uptake at 37°C is shown in Fig 1B. Ligand was not internalized if cells were not warmed to 37°C (Fig lB, 0 -minute panel). However, after only a brief period at 37"C, ligand was internalized (Fig lB, 5 -minute panel) and concentrated in a low-density fraction (fraction 7). Appearance of this peak could be inhibited completely by the presence of excess unlabeled ligand during the prebinding and internalization intervals (not shown). 12SI-transferrin internalized for 5 minutes demonstrated an identical density pattern.27 After more prolonged incubation at 37"C, the internalized 12sI-Iabel distributed progressively to fractions of higher density. After a delay of 20 minutes, there was a time-dependent rapid decline in the total amount of intracellular 12sI-label.
To elucidate the molecular form of internalized ligand, equal volume aliquots of fractions 7 and 2 were analyzed by SDS-PAGE and autoradiography. Results are shown in Fig  1C. The predominant form of internalized ligand was an SDS-stable complex of *ZsI-t-PA and PAI-1. In separate experiments, the identity of the complex as lzsI-t-PA.PAI-l (molecular weight, 95 Kd) was established by selective immunoprecipitation with monospecific anti-t-PA and anti-PAI-1 antibodies.I9 The integrity of the complex was maintained while it was associated with vesicles of low or intermediate buoyant density (fractions 7 to 4). However, the complex was degraded shortly after association with vesicles of high buoyant density (fractions3 to 2). Disappearance of the complex preceded loss of radioactivity from the cell. These data suggest that internalized IZSI-t-PA.PAI-l progressively transits early, intermediate, and late endosomes before degradation.
Intracellular routing of 1251-t-PA~PAI-I.
P-hexosominidose
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Intemalized 12sI-t-PA.PAI-I is targeted to lysosomes. To identify unambiguously the locus 12sI-t-PA*PAI-l degradation, the subcellular distribution of a ligand cohort internalized for selected intervals was determined using 25.2% Percoll to generate a density gradient capable of separating endosomes from lysosomes.2x-3n The density profile of this gradient was relatively shallow between 1.05 and 1.07 g/mL, but decreased below or increased sharply above these inflexion points (Fig 2A, left panel) . The lysosomal marker @-hexosaminidase, or cathepsin D (not shown), had a bimodal density distribution with peak activity in fractions 2 and 17 (Fig 2A, center panel) . Different populations of endosomes marked with internalized lZSI-transferrin could not be resolved on this gradient and were confined to fractions with densities less than 1.05 g/mL (not shown). Protein distribution was confined largely to the top of the gradient (Fig 2A, right panel) . The distribution of internalized ligand as a function of time at 37°C is depicted in Fig  2B. After short intervals of internalization, ligand concentrated in fraction 15 corresponding to the position of endosomes (Fig 2B, 5 -and 10-minute panels). After 20 minutes, a bimodal distribution of the label was apparent, concentrating in fractions 4 and 15. Although the bimodal pattern persisted when cellular contents were fractionated after longer periods of ligand uptake, the distribution of the 12sI-label shifted progressively to the higher-density position. There was also a time-dependent decline in total radioactivity retained within the cell. The molecular size of the 1251-labeled species present in fractions 15 and 4 is shown in Fig 2C. Aliquots containing approximately equal amounts of radioactive material wcre analyzed. The internalized lZsI-t-PA*PAI-l complex accumulated initially in fraction 15 and subsequently was detected transiently in fraction 4 before ligand degradation. These data indicate that the integrity of the ligand is maintained during endocytosis and delivery to a degradative compartment containing markers of mature lysosomes.
Perturbations of lysosomal function retard ligand degradation. The transient accumulation and subsequent degradation of internalized lZSI-t-PA.PAI-l in subcellular fractions containing acid hydrolases is consistent with catabolism of ligand occurring in lysosomes. To confirm this interpretation, the effects of selected lysosomotropic agents on ligand degradation were characterized. Exposure to the weak base primaquine neutralizes the acidic contents of vesicles and thereby inhibits acid-dependent cellular processes such as the function of lysosomal enzymes.3s--"x As shown in Fig 3, primaquine also affects degradation of 12sI-t-PA.PAI-1 by Hep G2 cells. Specific ligand uptake was diminished but not abolished by primaquine. This finding is consistent with the known inhibitory effect of primaquine on receptor recycling but not on endocytosis in several other receptor-ligand system^.^^.^^^^ Preexposure to primaquine was found to reduce the number of surface binding sites for IzsI-tPAePAI-1 to 69% of control without affecting binding affinity in eight separate isotherms at 4°C. Furthermore, maximal effect was seen with 200 pmol/L primaquine and after preincubation for only 10 minutes (not shown). In contrast to its limited effect on ligand uptake, primaquine inhibited specific ligand degradation almost completely. Inhibition could have resulted either from inadequate delivery of internalized ligand to the degradative compartment or from a direct impairment of catabolism. To distinguish between these possibilities, a prebound ligand cohort was internalized in the presence of primaquine. After selected intervals of internalization, the subcellular distribution of the ligand was determined using methods described for Figs 1 and 2 . In the presence of primaquine, internalized ligand accumulated in high-density gradient fractions containing lysosomal marker enzymes (not shown).
To confirm and extend these findings, the effects of several other agents on continuous uptake and catabolism of lZSI-t-PA.PAI-l over 3 hours were assessed (Table 1) . Similar to primaquine, chloroquine and ammonium chlo- ride are weak bases that increase the pH of acidic intracellular compartments such as endosomes and lysosomes. Accordingly, these agents can interfere with acid-dependent processes such as ligand-receptor dissociation or the activity of lysosomal acid hydrolases. Compared with primaquine, chloroquine and ammonium chloride also inhibited '%t-PA.PAI-l degradation markedly. However, the slightly divergent effects of these agents on ligand uptake may reflect their differing influences on other processes such as receptor recycling or ligand diacytosis.4042 In contrast to the weak base amines, the effects of the lysosomal proteinase inhibitors leupeptin and pepstatin A are confined primarily to catabolic steps in the uptake/degradation pathway.39 A combination of leupeptin and pepstatin A inhibited lZ5I-t- Monolayers of lo6 Hep G2 cells were preincubated with selected lysosomotropic agents for 30 minutes at 37°C. The 3 nmol/L 1Z51-t-PA was added with or without 1 ymol/L t-PA to allow formation, binding, uptake, and degradation of 1251-t-PA.PAI-1. After 3 hours, specific ligand uptake and degradation were determined as described in the text.
Results are expressed as means of duplicate determinations.
PA.PAI-1 degradation moderately. Persistent low-level degradation of ligand is consistent with incomplete inhibition of all participating proteinases by these agents. The augmentation in cell-associated ligand probably reflects continued endocytosis and receptor recycling superimposed on impaired ligand degradation when these agents were present. Density gradient fractionation of vesicles containing 12%t-PA.PAI-1 internalized in the presence of leupeptin and pepstatin A confirmed that ligand accumulated in fractions containing lysosomal markers (not shown). PAI-1 resists rapid lysosomal degradation. Receptormediated endocytosis of 1251-t-PA.PAI-1 by Hep G2 cells leads rapidly to catabolism of t-PA and discharge of 1251-labeled ligand fragments from the cell. Furthermore, the results described above suggest strongly that lysosomes are the locus of ligand degradation. Although PAI-1 remains complexed with t-PA until the ligand reaches the compartment responsible for degradation, the subsequent fate of the PAI-1 moiety is not known. To address this issue, 1251-label was incorporated into the PAI-1 molecule rather than into t-PA. A preparation containing functional PAI-1 was labeled with lZsI under conditions in which the inhibitory activity of PAI-1 is maintained.*l As seen in Table 2 , specific binding of lZI-t-PA.PAI-1 generated both in situ as well as preformed is specifically competed by 100-to 1,000-fold excess unlabelled t-PA.PAI-1 also generated both in situ as well as preformed. In addition, specific binding of preformed t-PA.1251-PAI-1 is specifically competed by unlabelled t-PA.PAI-1 generated both in situ as well as preformed. To examine the fate of the PAI-1 moiety, 1251-PAI-1 was reacted with unlabeled t-PA to generate a lZI-PAI-1 complex (Fig 4B, left panels) . The mixture containing preformed t-PA1251-PAI-1 was incubated with Hep G2 cell monolayers for 2 hours at 4°C to allow ligand binding. Specificity of binding was confirmed in parallel experiments in which the presence of excess unlabeled t-PA.PA1-1 inhibited t-PA.1251-PAI-l binding by more than 80% (see also Table 2 ) . Compared with an excess of preformed complex, unlabeled t-PA.PAI-1 generated in situ was equally effective as a competitor. After the prebinding period, cells were warmed to 37°C for selected intervals to permit ligand uptake. The subcellular distribution (Fig 4A) and molecular size (Fig 4B, center and After specific uptake at 37°C for 30 minutes or more, cell-associated 1251-label was confined almost exclusively to dense subcellular fractions (fractions 1 to 4) shown previously to contain lysosomal markers (Fig 1A) . In contrast to the data depicted in Fig 1, there was little decrement in cell-associated radioactive material with time. To identify changes in the molecular form of internalized label as a function of time, equal amounts of radioactivity from fractions 7 and 2 were analyzed by SDS-PAGE and autoradiography. In addition, equal sample volumes (fraction 7 for 5 minutes) were analyzed to quantify the effect of excess unlabeled t-PA-PAI-1 as a competitor for labeled ligand binding and uptake. After 5 minutes of uptake, the intracellular ligand was in the form of an SDS-stable 95-Kd t-PA.'251-PAI-1 complex. There were no specifically bound/ internalized lower molecular weight species. However, after 60 minutes the lzI-label was distributed among several bands of lower apparent molecular mass. The predominant band at 46 Kd comigrated with 12sI-PAI-1. The bands at approximately 25 Kd and at the dye front probably represent partial degradation fragments of PAI-1. After 180 minutes, the distribution of lZSI-label had altered only marginally, with a modest increase in intensity of the two bands of lower apparent molecular mass. Undegraded 1251-PAI-l still constituted a substantial proportion of the intracellular label 3 hours after ligand uptake.
The respective catabolic rates for the proteinase (t-PA) and serpin (PAI-1) moieties of an internalized t-PA.PAI-1 cohort were compared by quantifying the cumulative amount of degraded ligand that was discharged from Hep G2 cells as a function of time (Fig 5) . Experimental conditions were identical to those described for Figs 1 and 4 with 1251-label incorporated into either the t-PA or the PAL1 component of the t-PA-PAI-1 complex. Solubility of 1251-labeled ligand fragments in trichloroacetic acid was used as a measure of ligand degradation. After internalization of 1251-t-PA-PAI-l complexes, 12SI-labeled ligand fragments began to appear in the media only after a delay of 20 minutes. Subsequently, there was a sharp increase in the cumulative amount of degraded ligand discharged from the cells. In contrast, after internalization of t-PA.12SI-PAI-1 complexes, there was virtually no detectable discharge of labeled ligand fragments until 120 minutes after uptake. Thereafter, a slow increase in release of degraded ligand fragments occurred. After 180 minutes, cumulative degradation and release represented only 9% of the total amount of ligand bound. 
DISCUSSION
Our previous studies have shown that specific catabolism of t-PA by Hep G2 cells occurs as an orderly stepwise process.ls Exogenous t-PA complexes with endogenous PAI-1 that is anchored and stabilized in extracellular matrix by v i t r~n e c t i n .~~ After formation in extracellular matrix, the t-PA.PAI-1 adduct is released rapidly.19x20 This complex then binds specifically and with high affinity to a cell-surface receptor. Receptor binding is independent of the oligosaccharide components of t-PA and appears to be mediated through determinants on the PAI-1 moiety and/or the catalytic domain of t-PA.21,22 Surface-bound t-PA.PAI-1 undergoes receptor-mediated endocyto~is.~~ The results of this study indicate that internalized complex is targeted to lysosomes. However, the fates of the two components of the ligand differ markedly upon reaching this compartment. Whereas t-PA is degraded promptly and released, PAI-1 resists rapid catabolism and is retained intracellularly for a prolonged interval.
The observed divergent fates of the t-PA and PAI-1 moieties in Hep G2 lysosomes could conceivably reflect differences in the methods used either for purification and labeling of components or for generating the ligand complexes. Several lines of evidence indicate that this is not the case. The t-PA molecule is relatively stable, and we have shown previously that 1Z51-labeled t-PA reflects with fidelity the chemical, biochemical, and biologic properties of unlabeled t-PA.l8 Because the activity of PAI-1 is known to be labile and sensitive to oxidants, purification and labeling procedures potentially could have profound effects on this molecule. Precisely because of these concerns, we previously characterized the biologic activity of our lZ5I-labeled PAI-1 preparation extensively and showed that its behavior is indistinguishable from that of unlabeled PAI-1.21,23,43 In particular, we showed that it inhibits enzymatic activity of t-PA by forming SDS-stable complexes, that it similarly complexes with catalytically active forms of urokinase but not with the single-chain precursor form, that it mediates binding of t-PA complexes to a receptor on Hep G2 cells, that it binds to isolated extracellular matrix preparations, and that it interacts specifically with vitronectin both in solution and in extracellular matrix. In addition, 1251-PAI-l complexes with and inhibits both activated protein C and kallikrein (unpublished data). All of these phenomena are known characteristics of PAI-1. Thus, 1251-PAI-1 accurately reflects the biologic behavior of its unlabeled counterpart. Furthermore, using these 1251-t-PA or 1251-PAI-l preparations, we showed that 1251-t-PAPAI-l complexes generated in situ, and t-PA.lZ5I-PAI-1 complexes formed in vitro from the purified components, are similarly indistinguishable in terms of biologic a~t i v i t y . '~-~l ,~~ Complexes generated by either method bind specifically to Hep G2 cells at 4°C. For each labeled form of the complex, binding was inhibited by excess unlabeled ligand, and inhibition was independent of whether the competitor had been generated in situ or in vitro from purified unlabeled components. Data presented in the current study show that kinetics of ligand internalization at 37°C and the intracellular itinerary also are indistinguishable for complexes generated by either method. Because the events governing ligand binding, internalization, and intracellular routing appear to be identical for complexes generated by either method, Iysosomal processing events are expected to be independent of the methods used for preparation of the differently labeled complexes.
In most cells, common mechanistic features and morphologic structures characterize receptor-mediated surface binding and internalization of ligands destined for intracellular d e g r a d a t i~n .~~,~ In particular, many ligands are internalized with their specific receptors and proceed along a pathway involving successively coated pits, coated vesicles, endosomes, and lysosomes. Our results suggest that the itinerary of internalized t-PA.PAI-1 in Hep G2 cells is similar. After progressively longer intervals of uptake, a cohort of internalized t-PAPAI-1 molecules concentrated sequentially in subcellular fractions (Figs 1 and 4) with buoyant densities characteristic of increasingly mature en do some^.^^ Furthermore, after short intervals of uptake ( < 5 minutes), 1251-t-PA.PAI-1 localized in the same density fractions as internalized 1251-transferrin (not shown). Results of earlier morphologic studies had established the presence of transferrin exclusively in endosomes under these condition^.^^,^^ In addition, our results provide evidence that degradation of internalized t-PAPAI-1 occurs primarily in lysosomes. After uptake, t-PA.PAI-1 was targeted to subcellular fractions containing lysosomal markers (Figs 1,2, and 4) . The presence of selected inhibitors of lysosomal function caused accumulation of intact ligand in fractions containing lysosomes (not shown) and retarded ligand degradation (Fig 3 and Table 1 ). However, these findings cannot exclude a contribution to ligand degradation by very late endosomes that are difficult to separate from lysosomes and may contain acid hydrolase markers.41 Despite superficial similarities to endocytosis in other ligand systems, the detailed mechanisms of t-PA.PAI-1 uptake and processing are distinct in several respects. For example, t-PA-PAI-1 dissociates from its receptor only slowly at pH 5 (dissociation tlI2, > 200 minutes; not shown).
In contrast, a similar acidic milieu is known to promote rapid dissociation of several other ligands from their respective receptors on the cell surface or in en do some^.^' Although kinetic evidence suggests that the t-PA.PAI-1 receptor recycles rather than being degraded,ls the biochemical events responsible for ligand-receptor dissociation have not yet been elucidated for this system.
After t-PA.lZ5I-PAI-l was targeted to lysosomes, the PAI-1 component appeared to resist rapid degradation (Figs 4 and 5) . However, slow partial degradation occurred over several hours (Fig 4B) . While it is extremely difficult to prove explicitly, several lines of evidence suggest that the observed partial degradation products were derived exclusively from PAI-1 rather than from fragments of t-PA bound to parts of PAI-1 in an SDS-resistent manner. For instance, after 1251-t-PA.PAI-l was internalized, ligand degradation proceeded rapidly and resulted in formation and release of 1251-labeled fragments with an apparent molecular mass lower than 1 Kd, consistent with degradation to the level of small peptides or individual amino acids (Figs 1, 2, and 5 ). With t-PA.lZ5I-PAI-1, the apparent molecular mass of the internalized ligand also declined rapidly. However, degradation was incomplete during the interval of observation, and a species (47 Kd) that comigrated with authentic 1251-PAI-l was the predominant product detected (Fig 4B) . No fragments with apparent molecular masses intermediate between those of the t-PA.PAI-1 complex and PAI-1 were observed. Furthermore, there was minimal appearance of labeled fragments with apparent molecular mass lower than 47 Kd during the short interval required for t-PA degradation. These findings are consistent with rapid complete degradation of t-PA followed by slow proteolytic processing of PAI-1 within lysosomes. In additional experiments using purified components, we showed that PAI-1 and lZI-PAI-l are indeed susceptible to slow proteolytic modification by several proteolytic enzymes, including t-PA, activated protein C, and kallikrein (unpublished data). In each instance, a pattern of partial degradation of PAI-1 indistinguishable from that depicted in Fig 4B was observed. Because there is no apparent structural similarity between t-PA, protein C, and kallikrein, it is unlikely that a similarly sized unlabeled fragment would remain associated with PAI-1 in each case. Thus, the lZI-labeled degradation products depicted in Fig  4B represent fragments of lZI-PAI-1 rather than remnants of a proteinase-inhibitor complex.
The chemical basis for the relative stability of PAI-1 compared with t-PA after delivery to lysosomes (Figs 1,2,4 , and 5) is not entirely clear. However, PAI-1 maintains its structural integrity and functional activity after exposure to conditions of low P H .~~ Also, its inhibitory capacity in vitro extends to other proteinases besides t-PA.48,49 Accordingly, these factors may contribute to its relative stability in the presence of lysosomal acid hydrolases. Despite these characteristics, the residual intact PAI-1 moiety was not observed to form new SDS-stable complexes with other components present in the lysosome after t-PA was degraded. Similarly, the addition of t-PA to freeze-thaw disrupted lysosomes containing lZI-PAI-1 (fraction 2 after 30 or 60 minutes of ligand uptake, Fig 4) did not result in the formation of new t-PA.lzI-PAI-l complexes (not shown). In this assay, the presence of lysosomal proteinases could have degraded the added t-PA, thereby precluding complex formation and detection. Thus, whether residual PAI-1 retains activity after t-PA is degraded is uncertain. Likewise, the possible physiologic significance of the resistance of internalized PAI-1 to rapid degradation has not been established. Conceivably, the intact fraction of PAI-1 in lysosomes could be salvaged and reused, eg, by being redirected to the secretory pathway for eventual delivery to extracellular matrix or to media. Alternatively, the role of PAI-1 may be exclusively sacrificial with a specific function of ensuring delivery to t-PA to lysosomes. Eventually, the PAI-1 moiety could be degraded completely to low molecular mass products, albeit at a much slower rate than occurs with t-PA. The partial degradation of PAI-1 that occurred during intervals of observation up to 3 hours (Figs 4 and 5) supports this hypothesis.
Because of its contribution to both intracellular and extracellular processes, PAI-1 is a pivotal modulator of multiple steps in the catabolic pathway for t-PA by Hep G2 cells. Similar inhibitor-modulated events may characterize recognition, binding, endocytosis, intracellular trafficking, and catabolism of other proteinases and may contribute to their regulation under physiologic conditions.
